Poslechněte si podcast Surfing the MASH Tsunami

S6.13.3 - Major Issues in MASH-ville: US Government Chaos and Scanning Market Dynamism	Surfing the MASH Tsunami	37:13
S6.13.2 - Newsmakers: Updating Our Approach to Screening for Advanced Liver Disease	Surfing the MASH Tsunami	20:19
S6.13.1 - Major Issues in MASH-ville: Developing a More Integrated Approach to MASH Patient Management	Surfing the MASH Tsunami	19:48
S6.13 - Locating MASH patients, Population Screening for Advanced Disease, Impact of Washington on Americans' Health	Surfing the MASH Tsunami	73:53
S6.12.3 - After the Semaglutide Approval: What Next For MASH Therapy?	Surfing the MASH Tsunami	21:39
S6.12.2 - After the Semaglutide Approval: Expanding MASH Awareness Will Change Medical Practices	Surfing the MASH Tsunami	22:58
S6.12.1 - After the Semaglutide Approval: Impact on Patients and Pharmacotherapy	Surfing the MASH Tsunami	24:35
6.12 - A Second US Drug Approval! What Semaglutide's Success Portends For MASLD Care in the US	Surfing the MASH Tsunami	64:23
6.11.3 - Expert: Emily Andaya Asks Why There Is No "L" In the (Multi-Meatbolic) CKM Initiative	Surfing the MASH Tsunami	41:03
6.11.2 - Multi-Metabolic Week Part II: Benefits of the Multi-Metabolic Approach	Surfing the MASH Tsunami	43:59
6.11.1 - Multi-Metabolic Week Part I: Role of MASLD In Multi-Metabolic Clinics	Surfing the MASH Tsunami	37:34
6.11 - Multi-Metabolic Practices Integrate MASLD with Other Non-Communicable Diseases	Surfing the MASH Tsunami	109:45
6.10.3 - Expert: Tim Jobson on Using Basic Data and Analytics to Identify At-Risk Patients	Surfing the MASH Tsunami	37:16
6.10.2 - Newsmakers: LiverRight Launches America's First Virtual Hepatology Clinic	Surfing the MASH Tsunami	30:49
6.10.1 - FIrst Six Months, Part I: The Promise of Proteomics For Developing Individualized Treatment Plans	Surfing the MASH Tsunami	27:36
6.10 - New Approaches to Patient Care: NIT-driven drug choices, Virtual Clinics, Large-Scale Screening	Surfing the MASH Tsunami	92:25
6.9.3 - Expert: Naim Alkhouri Discusses His Long Friendship with Stephen Harrison and His New Role at Summit Clinical Research	Surfing the MASH Tsunami	29:12
6.9.2 - Newsmaker: Fatty Liver Alliance President Mike Betel Discusses His 3rd Annual 30-Day Glucose Challenge	Surfing the MASH Tsunami	39:31
6.9.1 - #SLDThinkTank2025, Part III: Unique Challenge of Nutrition Management and Role Politicians Can Play	Surfing the MASH Tsunami	23:35
6.9 - Complexities of Behavior Change, Devices That Can Help, Future of Clinical Trials and MedEd	Surfing the MASH Tsunami	77:21
6.8.3 - Deep Dive into Drug Development IV: Other Modes Of Action; Metabolic vs. Pleiotropic Effects	Surfing the MASH Tsunami	16:59
6.8.2 - Newsmaker: GLI President and CEO Larry Holden discusses Changes in Washington and How We Can Proceed	Surfing the MASH Tsunami	31:08
6.8.1 - #SLDThinkTank2025 Part II: Complexities and Challenges of Behavior Change	Surfing the MASH Tsunami	16:40
6.8 - Hybrid Interventions; Washington Challenges; Two-Target Treatment	Surfing the MASH Tsunami	62:58
S6 - E7.3 - Deep Dive into Drug Development, Part III: NITs in Drug Development	Surfing the MASH Tsunami	14:55
S6 - E7.2 - Patient Advocate Jose Willemse on Patient-Centered Care	Surfing the MASH Tsunami	33:45
S6 - E7.1 - #SLDThinkTank2025 Part I: Hybrid Interventions Integrate AI and Human Care	Surfing the MASH Tsunami	22:33
S6 - E7 - Barcelona SLD Conference Highlight; NITs in Drug Development	Surfing the MASH Tsunami	69:20
S6 - E6 - Remembering Stephen Harrison and His Many Contributions to MASH	Surfing the MASH Tsunami	57:17
S6 - E5.2 - Newsmaker: Naga Chalasani on Real-World Experience Prescribing Resmetirom	Surfing the MASH Tsunami	26:18
S6 - E5.3 - Expert: Scott Friedman on Gene Therapy and Advances in Liver Science	Surfing the MASH Tsunami	23:23
S6 - E5.1 - FGF-21s and A Promising Future on Cirrhosis	Surfing the MASH Tsunami	24:24
S6 - E5 - Drug Development Week: FGF-21s, Cirrhosis, Resmiterom, Gene Therapies	Surfing the MASH Tsunami	69:00
S6 - E4.3 - Expert: Mazen Noureddin Reviews the Exciting MASLD Drug Development Environment	Surfing the MASH Tsunami	24:34
S6 - E4.2 - Newsmaker: Fatty Liver Alliance Founder Mike Betel Discusses the Increased Visibility of Patient Advocates	Surfing the MASH Tsunami	31:16
S6 - E4.1 - MASLD Drugs, SLD Spectrum Insights Suggest Bright Future	Surfing the MASH Tsunami	20:58
S6 - E4 - Reasons for optimism in MASLD drug development and patient advocacy	Surfing the MASH Tsunami	72:42
S6 - E3.3 - Expert: GLI's Jeff McIntyre discusses implications of FDA job cuts on MASH drugs	Surfing the MASH Tsunami	31:31
S6 E3.2 - Newsmakers: FibroSIGHT™ Brings Clinical Trial Analytics to the Clinic	Surfing the MASH Tsunami	28:57
S6- E3.1 - Roundtable: Spotting Tomorrow’s Trends in Today's MASLD Studies	Surfing the MASH Tsunami	15:02

S6.13.3 - Major Issues in MASH-ville: US Government Chaos and Scanning Market Dynamism

Surfing the MASH Tsunami

37:13

S6.13.2 - Newsmakers: Updating Our Approach to Screening for Advanced Liver Disease

Surfing the MASH Tsunami

20:19

S6.13.1 - Major Issues in MASH-ville: Developing a More Integrated Approach to MASH Patient Management

Surfing the MASH Tsunami

19:48

S6.13 - Locating MASH patients, Population Screening for Advanced Disease, Impact of Washington on Americans' Health

Surfing the MASH Tsunami

73:53